''These cases appear to form a clinical group of which the chief features are: marked cardiac hypertrophy, symptoms of cardiac insufficiency and occurrence of various types of arrhythmia. The hearts, at autopsy, all show hypertrophy of the muscle fibers; in others, there is also fibrosis. . . Whether these cases represent a single disease, observed at different stages of its development, or are to be regarded as of heterogeneous origin, cannot now be stated.''
FAMILIAL
In 1949, William Evans [4] , a London cardiologist, described patients with cardiac hypertrophy who were very similar to those described in the paper by Levy and von Glahn [3] except for its familial occurrence. He wrote:
''There is described in this paper a distinct syndrome having a definite clinical, cardiographic and pathological pattern . . . having regard to the specificity of the condition and its chief characteristics I propose to name it Familial Cardiomegaly.''
This was followed by a remarkable paper by Paré et al. published in 1961 [5] . It includes 30 members of five generations of a French Canadian family residing in Quebec in whom the condition was inherited in an autosomal dominant manner.
SUDDEN CARDIAC DEATH
A very important characteristic of HCM was described in 1958 by Teare, a London pathologist [6] . He described eight cases of hypertrophy which were so asymmetric that he thought that they might be benign cardiac tumors (Fig. 1) . Seven of these caused sudden death in young adults. The pathological picture was one of bizarre and disorganized muscle bundles associated with hypertrophy of individual muscle fibers and their nuclei. Teare named the condition ''Asymetrical Hypertrophy of the Heart.'' Figure 1 . Gross anatomy of the heart in a patient with familial HCM (Ref. [6] ).
LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
In 1958, I was head of the cardiac catheterization laboratory at the National Heart Institute in Bethesda, Maryland, where I worked closely with Andrew Glenn Morrow who was chief of cardiac surgery. It was in the very early days of open-heart surgery, which was a very complicated, risky procedure at the time.
We studied a young man of about 22 years with angina and dyspnea who had a high subaortic pressure gradient. We assumed that he had a congenital membranous subaortic stenosis, and that he was a good candidate for surgery. During surgery, I received a call from Dr. Morrow's nurse, who said that Dr. Morrow wanted me to come to the operating room immediately. When I arrived, he was agitated and said that there was no obstruction in the patient's left ventricle! The heart had been arrested with potassium citrate, and he had performed an aortotomy. He had inserted his finger into the outflow tract of the left ventricle and found no obstruction. He then inserted his other index finger through the left atrium into the left ventricular cavity where his fingers met. While we had no idea what caused the intraventricular pressure gradient, Morrow did appreciate that there was considerable left ventricular hypertrophy. The young man recovered uneventfully from the procedure. Several weeks later we encountered a second patient with almost identical findings [7] .
At about the same time, Sir Russell Brock, the leading cardiovascular surgeon in the United Kingdom at the time, described a 32-year-old man with angina pectoris and a heart murmur of subaortic stenosis. He too exhibited a subaortic intraventricular pressure gradient [8] . In his report, Brock stated:
''That this is not an isolated case is made clear by the experience of Dr. Glenn Morrow who tells me he has operated on two similar cases in two young men in their early twenties; both survived. He has kindly allowed me to mention these prior to his own report of them (Morrow and Braunwald, Circulation, in press, 1959).'' These two papers [7, 8] were published virtually simultaneously. And I think that it was the development of open-heart surgery that really put hypertrophic obstructive cardiomyopathy (HOCM) on the map. In 1960, we described three siblings who demonstrated three of the abovementioned cardinal features: left ventricular hypertrophy, familial association, and hemodynamic changes of left ventricular outflow tract obstruction (Fig. 2) . 
DYNAMIC OBSTRUCTION
The fifth feature is the dynamic nature of the obstruction. We observed that physiologic and pharmacologic interventions that alter the size of the ventricle and its contractility affect the presence and severity of obstruction. We observed that in patients with HCM but without an intraventricular pressure gradient, the obstruction can be provoked, or, if present, can be intensified with an infusion of isoproterenol, which by its combined inotropic and vasodilator actions reduces the size of the left ventricular tract and thereby intensifies the obstruction (Fig. 3) . Nitroglycerine, by reducing ventricular filling, has a similar action (Fig. 4) . 
TREATMENT
In 1961, Morrow described a surgical procedure to relieve the obstruction [11] .
He incised the greatly hypertrophied interventricular septum (cardiac myotomy) and then excised some tissue in the left ventricular outflow tract (cardiac myectomy). Substantial clinical and hemodynamic benefit was observed [12] .
In addition to surgical treatment we also thought about medical treatment. Given the intensification of obstruction with the beta-adrenergic agonist isoproterenol [10] , we considered the use of newly developed beta-blockers. In 1964 we reported their beneficial hemodynamic effects [13] and later the clinical benefits that they achieved [14] . It is gratifying that a half century after these therapies were described, beta-blockers remain the first-line pharmacologic treatment for HCM with outflow tract obstruction while the myotomy-myectomy procedure described by Morrow is the most widely used intervention. So I will end by pointing out that the first century was a very fascinating period in the history of HCM [15] . This condition was once considered to be very rare, but it is now recognized to occur once in every 2500 births, and is the most frequently occurring monogenic cardiac disorder [16] .
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